Mazdutide (also known as IBI362 or LY3305677), a mammalian oxyntomodulin analogue with a fatty acid side chain attached, is being developed as a once-weekly GLP-1 and glucagon receptor dual agonist for the treatment of obesity and type 2 diabetes. The gene discussed is GCG; the disease is obesity disorder.